Pazopanib HCL intermediates manufacturer
On December 20, 2018, Hainan Huayitaikang Pharmaceutical Co., Ltd. (hereinafter referred to as "Huayitaikang") developed and manufactured Metoprolol Succinate Sustained Release Tablets, which were declared in cooperation with Taiwan Ancheng International Pharmaceutical Co., Ltd., and approved by the US FDA for listing.
Metoprolol is a first-line drug in the treatment of hypertension, coronary heart disease, chronic heart failure and arrhythmia.
According to statistics, the annual sales of metoprolol succinate sustained-release tablets in the U.S. market is about 800 million US dollars. The product obtained FDA approval marks the transformation of Huayitaikang from a R&D enterprise to a R&D production enterprise, and will directly participate in the competition of the international high-end generic drug market.
